| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Stanton Marshall S. | SVP, Clinical & MD Affair | 1655 ROBERTS BLVD., NW, KENNESAW | /s/ Marshall Stanton | 04 Mar 2026 | 0001849615 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | AORT | Common Stock | Award | +21,838 | +54% | $0.000000* | 62,246 | 02 Mar 2026 | Direct | F1 | |
| transaction | AORT | Common Stock | Sale | $81,180 | -2,149 | -3.5% | $37.78 | 60,097 | 03 Mar 2026 | Direct | F2 |
| Id | Content |
|---|---|
| F1 | Represents performance stock units granted on February 28, 2025. One third (1/3) were issued on March 2, 2026. The remaining shares earned in connection with the February 2025 grant will be eligible to vest and be issued as follows: one third (1/3) on February 28, 2027; and one third (1/3) on February 28, 2028, assuming employment on the relevant vesting date. |
| F2 | These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. |